Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
This article was originally published in The Pink Sheet Daily
Executive Summary
Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.
You may also be interested in...
Deerfield To NitroMed: Not So Fast, Not So Cheap
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.
Deerfield To NitroMed: Not So Fast, Not So Cheap
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.
Isis Sees A “Fit” With Archemix In Developing Novel Oligonucleotide-Based Drugs
Firms enter strategic alliance that provides Archemix access to four hundred Isis patents for developing proprietary aptamer therapeutics.